COVID-19 Vaccine and Potentially Related Thromboembolic Events: Case Series

Eman EL-Sawalhy^1, , Essa Kadiri¹, Eiman Elhouderi¹, Mohammed Abdelhalim¹, Marwa Sokrab¹, Jamila Asif¹, Maher Khadra¹, Khansae Nowir¹, Ayman Daoud² and Faisal Musa³

¹Department of Internal Medicine, Beaumont Hospital-Dearborn, MI

²Department of Internal Medicine, Beaumont Hospital-Wayne, MI

³Division of Hematology & Oncology, Internal Medicine Department, Beaumont Hospital-Dearborn, MI

Cite this paper

Eman EL-Sawalhy, Essa Kadiri, Eiman Elhouderi, Mohammed Abdelhalim, Marwa Sokrab, Jamila Asif, Maher Khadra, Khansae Nowir, Ayman Daoud and Faisal Musa. COVID-19 Vaccine and Potentially Related Thromboembolic Events: Case Series. American Journal of Medical Case Reports. 2021; 9(11):527-531. doi: 10.12691/AJMCR-9-11-2

Abstract

The advent of multiple COVID vaccinations over the past year through an accelerated vaccine development process has led to concerns over its safety. The United States approved for emergency use the BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), ChAdOx1 nCoV-19 (Oxford-AstraZeneca), and the Ad26.COV2.S (Janssen/Johnson & Johnson) vaccines. Although these vaccines have had a high safety profile, rare but serious adverse events have been reported including pulmonary embolism (PE) and cerebrovascular thrombosis. In this case series, we identified three patients admitted to Beaumont Hospital with new onset of pulmonary thromboembolism shortly after receiving the Pfizer-BioNTech vaccine. Clinical and laboratory data were obtained and reviewed from the Epic charting system. The three patients included two male and one female patient. All were older than the age of 40, obese with a BMI > 30 kg/m^2, and had underlying vascular disorders including hypertension, coronary artery disease, and/or a history of a cerebrovascular accident. One patient was a current cigarette smoker, one had quit over 27 years ago, and the third patient never smoked. Two patients developed pulmonary embolism after the second dose of the Pfizer-BioNTech vaccine, while the third patient developed pulmonary embolism after the first dose. This case series illustrates a possible association between the Pfizer-BioNTech vaccine and the potential development of pulmonary thromboembolism, particularly in middle-aged, obese adults with underlying vascular disease. This is not surprising as recent research has seen higher incidence of thrombosis with other COVID-19 vaccinations including Moderna, Oxford-AstraZeneca, and Janssen/Johnson & Johnson. Identifying this possible association is crucial in early diagnosis and patient management, but more importantly in educating higher risk adults to avoid modifiable risk factors for venous thromboembolism including immobility, certain medications, and possibly postponing elective surgeries. Further prospective or retrospective cohort studies are warranted to assess this association.

Keywords

Pfizer-BioNTech vaccine, pulmonary embolism, deep venous thrombosis, safety

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	“Mortality Analyses.” Johns Hopkins Coronavirus Resource Center, coronavirus.jhu.edu/data/mortality.
[2]	Gandhi, Rajesh T., et al. “Mild or Moderate Covid-19: NEJM.” New England Journal of Medicine, 21 Apr. 2021.
[3]	Commissioner, Office of the. U.S. Food and Drug Administration, FDA, www.fda.gov.
[4]	“Coronavirus Disease 2019 (COVID-19).” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/coronavirus/2019-ncov/index.html.
[5]	Isaac See, MD. “Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination.” JAMA, JAMA Network, 30 Apr. 2021, jamanetwork.com/journals/jama/fullarticle/2779731.
[6]	Scully, Marie, et al. “Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 NCoV-19 Vaccination: NEJM.” New England Journal of Medicine, 16 Apr. 2021.
[7]	Carli, Giuseppe, et al. “Deep Vein Thrombosis (DVT) Occurring Shortly after the Second Dose of MRNA SARS-CoV-2 Vaccine.” Internal and Emergency Medicine, vol. 16, no. 3, 2021, pp. 803-804.
[8]	PINHO, Ana Catarina. “AstraZeneca's COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Platelets.” European Medicines Agency, 8 Apr. 2021, www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
[9]	PINHO, Ana Catarina. “COVID-19 Vaccine Janssen: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Platelets.” European Medicines Agency, 22 Apr. 2021, www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
[10]	Torjesen, Ingrid. “Covid-19: Risk of Cerebral Blood Clots from Disease Is 10 Times That from Vaccination, Study Finds.” BMJ, 2021.
[11]	Schultz, Nina H., et al. “Thrombosis and Thrombocytopenia after ChAdOx1 NCoV-19 Vaccination.” New England Journal of Medicine, 2021.
[12]	Fadar Oliver Otite, et al. “Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States.” Neurology. 2020 Oct 20; 95(16): e2200-e2213. Epub 2020 Aug 26.
[13]	Sharon Devasagayam, et al. “Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study.”PMID: 27435401.